+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

The Discovery and Innovation Award

Western New York BloodCare

This program has been established to promote, nurture and amplify scientific discovery and innovation in Western New York and the region. The WNYBC Discovery and Innovation Award will support basic, translational, and/or clinical research projects that will improve health outcomes, health equity, and/or preventing complications of hemophilia and/or hemostatic or thrombotic disorders.

The program invites proposals from higher education institutions and non-profit organizations that have a history and track record of serving the community of bleeding and clotting disorders. There is no age requirement, however, applicants must have an MD, PhD or equivalent; clearly state they have both independent research projects and independent resources; and have preliminary results/and or publications from their independent laboratory.

Grant Application Details

Budget must not exceed $150,000/year, for up to three years. Up to two grants will be awarded annually.

Deadline for emailing LOI to mwiseman@wnybloodcare.org is
Friday May 1st, 2026, 11:59pm Eastern

Please direct questions to mwiseman@wnybloodcare.org

FULL APPLICATION DUE DATE: July 15, 2026

GRANT START DATE: January 1, 2027

AI Based Application Success Predictor

1. Direct relevance to hemophilia, bleeding, or thrombotic disorders (highest predictor)

This is the most important predictor.

WNYBC specifically prioritizes projects that improve:

outcomes in hemophilia
bleeding disorders
thrombotic disorders
hemostasis research
clotting complications
inhibitor formation
hemophilic joint disease
von Willebrand disease and related disorders

Projects outside these disease areas are less likely to align with the program mission.

2. High likelihood of meaningful patient impact (very high predictor)

WNYBC states that priority will be given to applications with a:

"high likelihood for success in terms of significant impact"

for individuals with hemophilia and related disorders.

Competitive proposals typically demonstrate:

improved diagnosis
better disease management
reduction of complications
improved quality of life
prevention of morbidity
advancement of treatment strategies

3. Strong independent investigator profile

Eligibility requirements make this a major predictor.

Applicants must:

hold an MD, PhD, or equivalent
demonstrate independent research projects
have independent resources
provide evidence of preliminary results and/or publications from their own laboratory

This means established scientific independence is heavily valued.

4. Preliminary data and publication record

Unlike some high-risk seed grants, WNYBC explicitly expects applicants to show evidence of prior productivity.

Strong applicants typically present:

preliminary data
peer-reviewed publications
proof-of-concept findings
demonstrated expertise in the proposed area

These factors help establish feasibility and likelihood of success.

5. Collaboration with a Hemophilia Treatment Center (HTC)

This is one of the clearest published review preferences.

WNYBC specifically notes that priority is given to projects that:

include collaborative efforts with a Hemophilia Treatment Center
integrate clinical and research expertise
connect research directly to patient care

This is a distinctive advantage compared with many other foundations.

6. Training and workforce-development component

Another explicitly stated review criterion is the ability to:

provide training opportunities
mentor physician-scientists
support biomedical researchers
strengthen the future workforce in bleeding-disorder research

Applications that include trainees, fellows, or junior investigators may receive favorable consideration.

7. Diversity, health equity, and community impact

WNYBC's mission includes improving:

health equity
access to care
outcomes across diverse populations

Priority is given to proposals that promote diversity and inclusion in research participation, staffing, or collaborations.

8. Feasible translational or clinical research plan

Funded examples have included:

genomics studies identifying new coagulation pathways
mechanisms of thrombosis and hemostasis
inflammatory and metabolic complications in hemophilia

Successful projects generally combine scientific innovation with a realistic pathway to clinical relevance.

Specialties

Cancer

Others

Clinical Trials

Eligibility Requirements

The program invites proposals from higher education institutions (public/state controlled, private), and non-profit 501(c)(3) organizations that have a history and track record of serving the community of bleeding and clotting disorders. Principal Investigators/Program Directors (PI/PDs) who may apply are any individuals with the skills, knowledge, required resources, and who can apply through their organization. There is no age requirement, however, applicant must have an MD, PhD, or equivalent; clearly state they have both independent research projects and independent resources; and have preliminary results/and or publications from their independent laboratory. This Award is open to candidates conducting research at a U.S. based not-for-profit institutions by the start date of the award. Priority is given to applicants within HRSA Region II.

Sponsor Details

Sponsor Institute/Organizations: Western New York BloodCare

Sponsor Type: Corporate/Non-Profit

Address: 1010 Main St, Buffalo, NY 14202

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity